Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis

References

• Ramsey BW, Davies J, McElvaney NG, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-72
   PubMed Web of Science ®Google Scholar
• Davies JC, Wainwright CE, Canny GJ, et al.; Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219-25
   Google Scholar
• Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014;18:1-106
   Web of Science ®Google Scholar
• Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-807
   PubMed Web of Science ®Google Scholar
• MacDonald KD, McKenzie KR, Zeitlin PL. Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs 2007;9:1-10
   PubMedGoogle Scholar
• Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-30
   PubMed Web of Science ®Google Scholar
• Bradley JM, Blume SW, Balp MM, et al. Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J 2013;41:571-7
   PubMed Web of Science ®Google Scholar
• de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5
   PubMed Web of Science ®Google Scholar
• Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ, Jr., Naureckas ET, Robinson KA, et al.; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187:680-9
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Patient Registry Annual Data Report, 2013. Bethesda, MD: Cystic Fibrosis Foundation, 2014. https://www.cff.org/Our-Research/CF-Patient-Registry/. Accessed 1, February 2016
   Google Scholar
• Ziller V, Zimmermann SP, Kalder M, et al. Adherence and persistence in patients with severe osteoporosis treated with teriparatide. Curr Med Res Opin 2010;26:675-81
   PubMed Web of Science ®Google Scholar
• Ziller V, Wetzel K, Kyvernitakis I, et al. Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 2011;14:228-35
   PubMed Web of Science ®Google Scholar
• Huot L, Durieu I, Bourdy S, et al.; REMU study. Evolution of costs of care for cystic fibrosis patients after clinical guidelines implementation in a French network. J Cyst Fibros 2008;7:403-8
   PubMed Web of Science ®Google Scholar
• Dewitt EM, Grussemeyer CA, Friedman JY, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health 2012;15:277-83
   PubMed Web of Science ®Google Scholar
• CF Care Center Visits. Bethesda, MD: CF Foundation; 2014. https://www.cff.org/Living-with-CF/Treatments-and-Therapies/The-Treatment-Plan/CF-Care-Center-Visits/. Accessed 18, March 2016
   Google Scholar
• Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2:84-90
   PubMedGoogle Scholar
• Rowe SM, Heltshe SL, Gonska T, et al.; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014;190:175-84
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Goss CH. Tackling the increasing complexity of CF care. Pediatr Pulmonol 2015;50(40 Suppl):S74-9
   Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8:91-6
   PubMed Web of Science ®Google Scholar
• Ziaian T, Sawyer MG, Reynolds KE, et al. Treatment burden and health-related quality of life of children with diabetes, cystic fibrosis and asthma. J Paediatr Child Health 2006;42:596-600
   PubMed Web of Science ®Google Scholar
• Kettler LJ, Sawyer SM, Winefield HR, et al. Determinants of adherence in adults with cystic fibrosis. Thorax 2002;57:459-64
   PubMed Web of Science ®Google Scholar
• Myers LB, Horn SA. Adherence to chest physiotherapy in adults with cystic fibrosis. J Health Psychol 2006;11:915-26
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Tiddens H. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol 2012;47:523-33
   PubMed Web of Science ®Google Scholar
• Bregnballe V, Schiøtz PO, Boisen KA, et al. Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Prefer Adherence 2011;5:507-15
   PubMed Web of Science ®Google Scholar
• Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5:177-85
   PubMed Web of Science ®Google Scholar
• Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med 2013;19:687-91
   PubMed Web of Science ®Google Scholar
• Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10:258-64
   PubMed Web of Science ®Google Scholar
• Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003;35:207
   PubMed Web of Science ®Google Scholar
• Haynes RB, McDonald H, Garg AX, et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002;CD000011:1-50
   PubMedGoogle Scholar
• Sackett DL, Haynes RB, Gibson ES, et al. Patient compliance with antihypertensive regimens. Patient Couns Health Educ 1978;1:18-21
   PubMedGoogle Scholar
• O’Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 2013;310:1343-4
   PubMed Web of Science ®Google Scholar
• Silverman E. Tiger in the fiscal room: beware the increasing cost and number of orphan drugs. Manag Care 2013;22:10-14
   PubMedGoogle Scholar